CHST3-Related Skeletal Dysplasia: Comprehensive Disease-Characteristics Report

Executive summary

CHST3-related skeletal dysplasia is an ultra-rare, autosomal-recessive disorder of cartilage extracellular-matrix biosynthesis caused by biallelic pathogenic variants in CHST3, encoding carbohydrate sulfotransferase 3/chondroitin 6-O-sulfotransferase 1. Its historically separated diagnoses—spondyloepiphyseal dysplasia with congenital joint dislocations, spondyloepiphyseal dysplasia Omani type, chondrodysplasia with multiple dislocations, recessive Larsen syndrome, and humero-spinal dysostosis—are now best understood as a phenotypic spectrum. The cardinal findings are prenatal or congenital short stature, multiple congenital joint dislocations, abnormal epiphyses and vertebrae, and progressive joint and intervertebral-disc degeneration. Intelligence is generally normal. The molecular lesion is reduced chondroitin 6-O-sulfation; patient fibroblasts showed a four- to fivefold reduction in the relevant 6-sulfated chondroitin disaccharide. No disease-modifying therapy is established; management is multidisciplinary, orthopedic, rehabilitative, and surveillance-based. Evidence remains dominated by small cohorts and case series rather than registries or trials. (hermanns2008congenitaljointdislocations pages 2-4, hermanns2008congenitaljointdislocations pages 4-6, debeljak2023carbohydratesulfotransferases pages 3-5)

Table: This table summarizes high-confidence, knowledge-base-ready findings on CHST3-related skeletal dysplasia from the available cited evidence. It emphasizes the strongest cohort data, core mechanism, and current gaps that require direct database validation or newer primary sources.

1. Disease information

Definition and scope

CHST3-related skeletal dysplasia is a Mendelian proteoglycan-sulfation disorder affecting cartilage, joints, vertebral bodies, and intervertebral discs. Congenital dislocations arise from primary dysplasia of joint structures—not merely generalized ligamentous laxity—and are followed by progressive cartilage and spinal degeneration. The 2008 molecular delineation unified patients previously diagnosed with recessive Larsen syndrome and humero-spinal dysostosis; subsequent literature has incorporated Omani-type spondyloepiphyseal dysplasia and related multiple-dislocation phenotypes into the same CHST3 spectrum. (hermanns2008congenitaljointdislocations pages 4-6, hall2024fetalandperinatal pages 63-64)

Common names/synonyms include:

• CHST3-related skeletal dysplasia;
• spondyloepiphyseal dysplasia with congenital joint dislocations;
• spondyloepiphyseal dysplasia, Omani type;
• chondrodysplasia with multiple dislocations;
• autosomal-recessive multiple joint dislocations;
• recessive Larsen syndrome, CHST3-related;
• humero-spinal dysostosis, CHST3-related. (debeljak2023carbohydratesulfotransferases pages 3-5, hall2024fetalandperinatal pages 63-64)

Identifiers

• Gene: CHST3; standard transcript used in recent reviews: NM_004273.5. (debeljak2023carbohydratesulfotransferases pages 3-5)
• OMIM: CHST3 is commonly catalogued as 603799 and spondyloepiphyseal dysplasia with congenital joint dislocations as 143095; these identifiers should be revalidated directly in OMIM before production ingestion because the retrieved literature did not itself state them.
• MONDO: a dedicated current MONDO accession was not recoverable from the retrieved evidence. Use the specific CHST3-related disease concept where available rather than assigning the broad “skeletal dysplasia” parent; validate against the current MONDO release.
• Orphanet: exact ORPHA number was not stated in the retrieved sources and requires direct Orphanet validation.
• ICD-10/ICD-11: no disease-specific billing code was established. Broad congenital osteochondrodysplasia/spondyloepiphyseal-dysplasia categories may be used, but these lose molecular specificity.
• MeSH: “Osteochondrodysplasias” and “Spondyloepiphyseal Dysplasia” are appropriate parent concepts; no retrieved evidence established a dedicated CHST3-specific MeSH descriptor.

This report synthesizes aggregated disease-level resources and published patients, not individual EHR records. The strongest quantitative evidence available here is a six-patient molecular cohort. (hermanns2008congenitaljointdislocations pages 2-4)

2. Etiology, risk, and protective factors

Causal factor

The cause is germline biallelic loss-of-function or severe hypomorphic variation in CHST3, inherited in an autosomal-recessive pattern. Reported classes include missense, nonsense, frameshift, and splice-altering variants. In the foundational cohort, nine mutations across eight alleles included five missense, three premature-termination, and one splice-site mutation. (hermanns2008congenitaljointdislocations pages 2-4)

Representative variants include p.Tyr201Ter, p.Phe206Ter, p.Arg222Trp, p.Leu259Pro, p.Leu307Pro, p.Glu372Lys, and c.1086delG. A 2023 review additionally lists c.590T>C (p.Leu197Pro), c.603C>A (p.Tyr201Ter), c.661C>T (p.Arg221Cys), and c.802G>T (p.Glu268Ter). Transcript/version and left-alignment must be checked before variant-database ingestion. (hermanns2008congenitaljointdislocations pages 4-6, debeljak2023carbohydratesulfotransferases pages 3-5)

Risk factors

• Genetic: having two pathogenic CHST3 alleles is the decisive risk factor. Consanguinity increases the probability that both parents carry the same rare allele and was reported in affected families. (hermanns2008congenitaljointdislocations pages 2-4)
• Family history: an affected sibling substantially increases recurrence concern; for two confirmed heterozygous parents, the Mendelian risk is 25% affected, 50% carrier, and 25% unaffected/non-carrier per pregnancy.
• Sex: no evidence supports sex-dependent penetrance; males and females can be affected.
• Environmental, lifestyle, occupational, age-related, or infectious risks: none are established as causal or susceptibility factors for this congenital monogenic disorder.

Protective factors and gene–environment interaction

No validated protective CHST3 allele, modifier gene, diet, exposure, or lifestyle intervention prevents disease in a person with biallelic pathogenic variants. Likewise, no disease-specific gene–environment interaction has been demonstrated. Mechanical loading may influence downstream orthopedic morbidity, but this is not evidence that environment causes or prevents the molecular disorder.

3. Phenotypes

The following frequencies come from only six patients and should not be treated as population estimates. All six presented at birth with congenital dislocations and clubfeet; knee dislocation occurred in 6/6, hip luxation in 4/6, and radial-head dislocation in 6/6. Birth length was 41.5–44 cm, below the third percentile; adult height in the oldest reported individual was 134 cm. (hermanns2008congenitaljointdislocations pages 2-4)

Core manifestations and suggested HPO annotations

• Multiple congenital joint dislocations—congenital, severe, persistent; often knees, hips, elbows/radial heads. Suggested HPO concepts: congenital joint dislocation, dislocated knee, hip dislocation, radial-head dislocation. (hermanns2008congenitaljointdislocations pages 4-6, hermanns2008congenitaljointdislocations pages 2-4)
• Clubfoot/talipes equinovarus—congenital; 6/6 in the foundational cohort. Suggested HPO: clubfoot. (hermanns2008congenitaljointdislocations pages 2-4)
• Genu recurvatum—congenital knee hyperextension, reported in approximately 50% in the six-patient evidence summary. Suggested HPO: genu recurvatum. (hermanns2008congenitaljointdislocations pages 2-4)
• Disproportionate short stature—prenatal or congenital onset and persistent. Suggested HPO: short stature, prenatal-onset short stature, disproportionate short stature. (hermanns2008congenitaljointdislocations pages 2-4, hermanns2008congenitaljointdislocations pages 4-6)
• Epiphyseal/joint dysplasia and early degenerative arthropathy—progressive, producing pain, contractures, restricted movement, and hip arthritis. Suggested HPO: epiphyseal dysplasia, joint contracture, osteoarthritis, limited joint mobility. (hermanns2008congenitaljointdislocations pages 4-6)
• Spinal disease—vertebral-body clefting and widened lumbar interpedicular distances may be evident early; severe disc degeneration, thoracic kyphosis, kyphoscoliosis, and vertebral fusion develop with age. Suggested HPO: platyspondyly/abnormal vertebral morphology as appropriate to imaging, thoracic kyphosis, scoliosis, kyphoscoliosis, intervertebral-disc degeneration. (hermanns2008congenitaljointdislocations pages 2-4, hermanns2008congenitaljointdislocations pages 4-6)
• Upper-limb radiographic abnormalities—bifid/dysplastic distal humerus, radial-head subluxation or dislocation, and later metacarpal shortening. Suggested HPO: abnormality of the distal humerus, radial-head dislocation, short metacarpals. (hermanns2008congenitaljointdislocations pages 4-6)
• Hearing loss—included in the broader CHST3 spectrum by the 2023 review, but its frequency and typical onset were not quantified. Suggested HPO: hearing impairment; subtype only after audiologic characterization. (debeljak2023carbohydratesulfotransferases pages 3-5)
• Neurodevelopment: intelligence is generally normal. Cleft palate and myopia were not observed in the foundational cohort, so they should not be treated as defining features. (hermanns2008congenitaljointdislocations pages 4-6)

Functional and quality-of-life effects

Progressive contractures, arthritis, deformity, and disc disease substantially affect walking, self-care, education/employment access, pain, and independence. In reported patients aged 10.5–31 years, some required crutches or wheelchairs or lost independent ambulation. No disease-specific EQ-5D, SF-36, PROMIS, pain-scale, or caregiver-burden dataset was found. (hermanns2008congenitaljointdislocations pages 2-4)

4. Genetic and molecular information

CHST3 encodes chondroitin 6-O-sulfotransferase 1, a Golgi-associated sulfotransferase that modifies chondroitin chains of proteoglycans. The disease variants are germline, not somatic cancer mutations. Truncating and severe missense alleles reduce or abolish enzyme activity; p.Tyr201Ter and p.Phe206Ter truncate the sulfotransferase region, while p.Arg222Trp and p.Leu259Pro markedly impair function. (hermanns2008congenitaljointdislocations pages 4-6)

Patient-fibroblast studies demonstrated a four- to fivefold reduction in DDi-6S, the 6-sulfated chondroitin disaccharide product. This is direct human-cell functional evidence linking genotype to deficient chondroitin 6-O-sulfation. (hermanns2008congenitaljointdislocations pages 2-4)

No reliable variant-specific population frequencies were available in the retrieved texts. Individual alleles should be checked in current gnomAD and ClinVar releases; pathogenic recessive alleles are expected to be absent or very rare, but rarity alone does not establish pathogenicity. ACMG/AMP classification should integrate segregation, predicted consequence, functional evidence, population frequency, and phenotype specificity.

No validated modifier genes, disease-specific epigenetic signature, recurrent pathogenic copy-number variant, translocation, aneuploidy, or chromosomal rearrangement has been established. Consequently, routine karyotype or microarray is not the preferred confirmatory test when the phenotype strongly suggests CHST3 disease.

5. Environmental information

No toxin, radiation source, pollutant, diet, smoking behavior, alcohol exposure, occupation, or infectious agent is known to cause CHST3-related skeletal dysplasia. Environmental factors can affect general bone health, surgical recovery, pain, and mobility but should be represented as modifiers of health status—not etiologic disease assertions. Immunization and antimicrobial interventions have no disease-specific preventive role.

6. Mechanism and pathophysiology

Causal chain

1. Upstream genetic trigger: biallelic pathogenic CHST3 variants.
2. Protein-level defect: absent or reduced carbohydrate sulfotransferase 3 activity in the Golgi.
3. Biochemical defect: inadequate 6-O-sulfation of N-acetylgalactosamine residues in chondroitin sulfate; patient fibroblasts show a four- to fivefold reduction in the 6-sulfated disaccharide product. (hermanns2008congenitaljointdislocations pages 2-4)
4. Matrix-level consequence: altered sulfation changes proteoglycan physical properties and interactions within cartilage extracellular matrix. Carbohydrate sulfotransferases normally support proteoglycan-mediated cell–cell and cell–matrix signaling. (debeljak2023carbohydratesulfotransferases pages 3-5)
5. Developmental consequence: impaired organization and biomechanical performance of growth-plate, epiphyseal, articular, vertebral, and intervertebral-disc cartilage.
6. Clinical consequence: prenatal growth disturbance and malformed joint surfaces produce congenital dislocations; chronic abnormal loading plus intrinsically abnormal matrix produces progressive contractures, arthritis, disc collapse, kyphosis/kyphoscoliosis, and mobility loss. Dislocations are therefore interpreted as primary joint dysplasia rather than simple laxity. (hermanns2008congenitaljointdislocations pages 4-6)

Suggested ontology annotations

• GO biological process: glycosaminoglycan biosynthetic process; chondroitin sulfate biosynthetic process; proteoglycan metabolic process; cartilage development; endochondral ossification; extracellular-matrix organization.
• GO molecular function: sulfotransferase activity; carbohydrate sulfotransferase activity.
• GO cellular component: Golgi apparatus/Golgi membrane; extracellular matrix for the affected downstream substrate compartment.
• Cell Ontology: chondrocyte; growth-plate chondrocyte where supported; fibroblast for the functional assay. Exact CL accessions should be validated against the current release.

No CHST3-disease-specific single-cell atlas, spatial transcriptomic study, patient proteome, metabolome, lipidome, multi-omics integration, organoid study, or CRISPR screen was established by the retrieved literature. These are important research gaps.

7. Anatomical structures affected

The primary system is the musculoskeletal/connective-tissue system.

• Organs/structures: appendicular skeleton, joints, spine, and intervertebral discs.
• Specific sites: hips, knees, elbows/radial heads, feet, distal humeri, metacarpals, vertebral bodies, and thoracic/lumbar spine. (hermanns2008congenitaljointdislocations pages 2-4, hermanns2008congenitaljointdislocations pages 4-6)
• Tissues: hyaline cartilage, articular cartilage, growth-plate cartilage, epiphyseal cartilage, fibrocartilage of the intervertebral disc, and proteoglycan-rich extracellular matrix.
• Cells: chondrocytes are the principal inferred disease-relevant population; fibroblasts have provided direct biochemical assay evidence.
• Subcellular compartment: Golgi apparatus for CHST3-mediated sulfation; extracellular matrix for the downstream defective chondroitin-sulfate proteoglycans.
• Lateralization: typically multiple and often bilateral rather than a consistently unilateral process.

Suggested UBERON concepts include cartilage tissue, articular cartilage, epiphyseal plate, intervertebral disc, vertebral body, hip joint, knee joint, elbow joint, humerus, radius, and foot; exact accessions should be version-validated.

8. Temporal development

The disorder begins prenatally or congenitally, with short length, joint malformation, dislocations, and clubfeet apparent at birth. The course is chronic and lifelong rather than episodic. Childhood and adolescence bring increasing joint restriction, contractures, deformity, and spinal disease; older patients can develop severe disc degeneration, kyphoscoliosis, vertebral fusion, arthritis, and loss of independent mobility. (hermanns2008congenitaljointdislocations pages 2-4, hermanns2008congenitaljointdislocations pages 4-6)

There is no recognized spontaneous remission. The most important intervention window is early childhood, when joint alignment, spine stability, mobility preservation, and avoidance of secondary deformity may be addressed. However, no prospective study defines an optimal operation age or stage-specific algorithm.

9. Inheritance and population

Inheritance is autosomal recessive. Penetrance appears high for individuals with two severe pathogenic alleles, but formal age-adjusted penetrance has not been calculated. Expressivity is variable, including intrafamilial variation, and the historic use of multiple diagnostic names reflects this breadth. No anticipation mechanism is expected or documented. Germline mosaicism has not been established but cannot be excluded in apparently de novo situations.

Consanguinity is a relevant population-genetic factor, and patients have been described in Omani/Arab, Pakistani, Turkish, Indian, Somali, Mediterranean, and other families. A recurrent c.776T>C allele has been reported in later literature, but robust founder-haplotype evidence was not available here. (debeljak2023carbohydratesulfotransferases pages 3-5, hall2024fetalandperinatal pages 63-64)

No credible prevalence, incidence, carrier-frequency, sex-ratio, mortality-rate, or geographic-rate estimate was found. The disorder should be classified as ultra-rare, with ascertainment biased toward consanguineous families and specialist skeletal-dysplasia centers.

10. Diagnostics

Clinical and imaging evaluation

Suspect CHST3-related disease in a neonate or child with multiple congenital dislocations, clubfeet, disproportionate short stature, radial-head abnormalities, and a spondyloepiphyseal radiographic pattern. Characteristic reported images include knee malalignment/dislocation, bifid distal humeri with radial-head subluxation, lumbar vertebral clefting, widened L1–L2 interpedicular distance, and later severe disc degeneration and vertebral fusion. (hermanns2008congenitaljointdislocations pages 4-6)

Baseline evaluation should include a skeletal survey interpreted by a skeletal-dysplasia radiologist; targeted spine, hip, knee, elbow, and foot imaging; neurologic examination where spinal deformity is substantial; audiology; growth measurements; pain and functional assessment; and orthopedic/rehabilitation review. MRI is useful for discs, spinal cord, neural compression, and operative planning but is not itself molecularly diagnostic.

No routine serum or urine chemistry is diagnostic. The fibroblast DDi-6S assay is mechanistically informative but is not established as a widely available clinical standard. (hermanns2008congenitaljointdislocations pages 2-4)

Genetic testing strategy

1. Preferred: next-generation skeletal-dysplasia panel including CHST3, with deletion/duplication analysis and full coverage of coding exons and splice boundaries.
2. Single-gene CHST3 testing: appropriate when phenotype and family variant are highly specific.
3. WES/WGS: useful for atypical disease, negative panels, consanguineous families, or phenotypic overlap; WGS may detect deep intronic or structural variants missed by routine sequencing.
4. Parental testing: establishes phase and segregation.
5. RNA studies: may clarify suspected splice variants when appropriate tissue/transcript is available.
6. CMA, karyotype, FISH, mitochondrial testing, and repeat-expansion testing: not first-line for an otherwise typical CHST3 phenotype.

Differential diagnosis

Important alternatives include FLNB-related dominant Larsen syndrome, B3GAT3- and other linkeropathy-associated multiple-dislocation disorders, CHST14-related musculocontractural Ehlers–Danlos syndrome, SLC26A2-related dysplasias, XYLT1-related Desbuquois dysplasia type 2, CANT1-related Desbuquois dysplasia, IMPAD1-related chondrodysplasia, and collagen-related spondyloepiphyseal dysplasias. Distinguishing features include inheritance, craniofacial pattern, hand morphology, skin/vascular signs, bone density, specific radiographic pattern, and molecular result.

No universally accepted clinical scoring criteria or population/newborn biochemical screening program exists.

11. Outcome and prognosis

The major burden is musculoskeletal morbidity: recurrent or persistent deformity, early arthritis, contractures, pain, severe disc degeneration, kyphosis/kyphoscoliosis, vertebral fusion, and impaired ambulation. Some patients require crutches or wheelchairs by later childhood or adulthood. (hermanns2008congenitaljointdislocations pages 2-4)

Intellectual prognosis is generally favorable. No reliable five- or ten-year survival rate, disease-specific mortality estimate, or life-expectancy calculation is available. Available evidence does not identify an intrinsic lethal cardiopulmonary, neurologic, or immune phenotype, but individual prognosis depends on spinal disease, operative complications, pain, and mobility. Formal prognostic biomarkers and validated patient-reported outcome measures have not been developed.

12. Treatment

There is no approved enzyme replacement, small-molecule, gene, RNA, or cell therapy for CHST3-related skeletal dysplasia. The retrieved clinical-trial search found no relevant interventional trial; an unrelated GLP-1 study returned by broad search was excluded.

Current care is individualized and multidisciplinary:

• orthopedic reduction, reconstruction, osteotomy, stabilization, or fusion for clinically consequential dislocations and deformity;
• serial spine surveillance and surgical management when progressive deformity, instability, pain, or neural compromise warrants it;
• physical and occupational therapy emphasizing safe mobility, range of motion, strengthening, adaptive function, and avoidance of injurious force;
• orthoses, crutches, walkers, wheelchairs, and environmental adaptations;
• analgesia following standard pediatric/adult pain principles;
• audiologic support if hearing loss is present;
• psychosocial, educational, and vocational support.

Most patients in the foundational series required multiple stabilization operations, but the evidence does not establish response rates or a single preferred surgical pathway. (hermanns2008congenitaljointdislocations pages 4-6)

Suggested NCIT intervention concepts include orthopedic surgical procedure, osteotomy, spinal fusion, physical therapy, occupational therapy, assistive device, pain management, and genetic counseling; exact NCIT identifiers should be release-validated. No CHST3-specific pharmacogenomic recommendation exists.

13. Prevention

The molecular disease cannot currently be prevented by diet, lifestyle modification, vaccination, or prophylactic medication.

• Primary genetic prevention/family planning: genetic counseling, carrier testing for relatives, reproductive-partner testing, preimplantation genetic testing for a known familial variant, and prenatal diagnosis by chorionic-villus sampling or amniocentesis.
• Secondary prevention: early molecular diagnosis and orthopedic/spinal surveillance to identify treatable deformity before irreversible disability.
• Tertiary prevention: rehabilitation, safe mobility, pain control, contracture prevention, fall-risk reduction, and management of spinal or arthritic complications.
• Cascade screening: appropriate for at-risk relatives after pathogenic familial variants are established.

Population-wide newborn or carrier screening is not currently supported by prevalence or utility data.

14. Other species and natural disease

No adequately supported naturally occurring veterinary analogue attributable to orthologous CHST3 variants was identified in the retrieved evidence. CHST3 is evolutionarily conserved, and chondroitin-sulfate biology is shared across vertebrates, but conservation alone is not evidence of a natural animal disease. There is no zoonotic potential or cross-species transmission because this is a germline genetic disorder.

Relevant taxonomy concepts for experimental comparisons include Homo sapiens (NCBI Taxon 9606) and Mus musculus (10090). Species-specific CHST3 ortholog and NCBI Gene identifiers should be retrieved directly from the current NCBI orthology record before ingestion.

15. Model organisms and experimental systems

The retrieved evidence did not provide sufficient primary detail to curate a specific CHST3-null mouse line, its accession, or quantitative phenotype with confidence. More broadly, glycosaminoglycan-biosynthetic knockout mice have been valuable for establishing how sulfation patterns regulate cell signaling, proliferation, tissue morphogenesis, and growth-plate/cartilage development. (debeljak2023carbohydratesulfotransferases pages 3-5)

The strongest disease-specific experimental model in the available evidence is patient-derived fibroblasts, which directly reproduced the biochemical sulfation defect. (hermanns2008congenitaljointdislocations pages 2-4)

Priority future models include:

• Chst3-null and patient-variant knock-in mice, with quantitative growth plate, epiphyseal, disc, and joint phenotyping;
• patient iPSC-derived chondrocytes and cartilage organoids;
• isotope- or mass-spectrometry-based chondroitin disaccharide profiling;
• rescue experiments using wild-type CHST3;
• cartilage-specific gene delivery or editing studies.

Model limitations must include species differences in skeletal loading, growth-plate closure, joint anatomy, and lifespan, and the inability of fibroblast assays to reproduce the biomechanical environment of human cartilage.

Recent research and expert assessment, 2023–2024

A peer-reviewed review published in October 2023 emphasized that carbohydrate sulfotransferases build proteoglycans supporting physical interactions and signaling between neighboring cells and summarized CHST3 mutations as causes of skeletal dysplasia, chondrodysplasia, and autosomal-recessive multiple dislocations. Its abstract states: “Mutations of CHST3 gene cause skeletal dysplasia, chondrodysplasia, and autosomal recessive multiple joint dislocations.” The authors cautioned that larger clinical studies and robust analytical procedures remain necessary. DOI: https://doi.org/10.11613/bm.2023.030503. (debeljak2023carbohydratesulfotransferases pages 3-5)

A March 2024 expert fetal/perinatal skeletal-dysplasia reference retained recessive Larsen syndrome, humero-spinal dysostosis, and Omani-type spondyloepiphyseal dysplasia within the autosomal-recessive CHST3/glycosaminoglycan-synthesis spectrum. DOI/book URL: https://doi.org/10.1201/9781003166948. (hall2024fetalandperinatal pages 63-64)

The most important recent disease-specific primary report identified by the search was a 2023 series titled CHST3-related skeletal dysplasia in 14 patients: identification of 8 novel variants and further expansion of the phenotypic spectrum (May 2023; DOI: https://doi.org/10.1002/ajmg.a.63246), but its full text was unavailable to the retrieval system. Accordingly, its title-level claims should not be converted into phenotype frequencies without direct verification.

Evidence-strength and data-gap statement

The foundational primary article, published in June 2008, reports: “We report eight CHST3 mutations in six unrelated individuals who presented at birth with congenital joint dislocations.” DOI: https://doi.org/10.1016/j.ajhg.2008.05.006; PMID commonly indexed as 18513679. It provides the strongest retrieved human genotype, phenotype, biochemical, and longitudinal evidence. (hermanns2008congenitaljointdislocations pages 2-4, hermanns2008congenitaljointdislocations pages 4-6)

Nevertheless, the evidence base remains limited by small, retrospectively ascertained cohorts. Critical unmet needs include a prospective natural-history registry; validated phenotype frequencies; standardized radiographic and functional endpoints; prevalence and carrier-frequency estimates; patient-reported quality-of-life measures; genotype–phenotype analysis; disease-specific biomarkers; well-curated model organisms; and interventional trials. Quantitative values from six patients must therefore be labeled as cohort observations rather than general disease frequencies.

References

1. (hermanns2008congenitaljointdislocations pages 2-4): Pia Hermanns, Sheila Unger, Antonio Rossi, Antonio Perez-Aytes, Hector Cortina, Luisa Bonafé, Loredana Boccone, Valeria Setzu, Michel Dutoit, Luca Sangiorgi, Fabio Pecora, Kerstin Reicherter, Gen Nishimura, Jürgen Spranger, Bernhard Zabel, and Andrea Superti-Furga. Congenital joint dislocations caused by carbohydrate sulfotransferase 3 deficiency in recessive larsen syndrome and humero-spinal dysostosis. American journal of human genetics, 82 6:1368-74, Jun 2008. URL: https://doi.org/10.1016/j.ajhg.2008.05.006, doi:10.1016/j.ajhg.2008.05.006. This article has 131 citations and is from a highest quality peer-reviewed journal.

2. (hermanns2008congenitaljointdislocations pages 4-6): Pia Hermanns, Sheila Unger, Antonio Rossi, Antonio Perez-Aytes, Hector Cortina, Luisa Bonafé, Loredana Boccone, Valeria Setzu, Michel Dutoit, Luca Sangiorgi, Fabio Pecora, Kerstin Reicherter, Gen Nishimura, Jürgen Spranger, Bernhard Zabel, and Andrea Superti-Furga. Congenital joint dislocations caused by carbohydrate sulfotransferase 3 deficiency in recessive larsen syndrome and humero-spinal dysostosis. American journal of human genetics, 82 6:1368-74, Jun 2008. URL: https://doi.org/10.1016/j.ajhg.2008.05.006, doi:10.1016/j.ajhg.2008.05.006. This article has 131 citations and is from a highest quality peer-reviewed journal.

3. (debeljak2023carbohydratesulfotransferases pages 3-5): Željko Debeljak, Gramos Begolli, Ivana Marković, and Jelena Knežević. Carbohydrate sulfotransferases. Biochemia medica, 33:255-265, Oct 2023. URL: https://doi.org/10.11613/bm.2023.030503, doi:10.11613/bm.2023.030503. This article has 29 citations and is from a peer-reviewed journal.

4. (hall2024fetalandperinatal pages 63-64): Christine M Hall, Amaka C Offiah, Francesca Forzano, Mario Lituania, Gen Nishimura, and Valerie Cormier-Daire. Fetal and perinatal skeletal dysplasias. ArXiv, Mar 2024. URL: https://doi.org/10.1201/9781003166948, doi:10.1201/9781003166948. This article has 26 citations.

Artifacts

• Edison artifact artifact-00